BioCardia scuttles IPO; Dauntless Pharma raises $12M A round;

@FierceBiotech: ICYMI: 'Cures' bill, designed to speed drug approvals, could be too much of a good thing, dissenters say. Story | Follow @FierceBiotech

@JohnCFierce: Schoenebaum sees great stuff in $BIIB data, predicts a rise in share price. | Follow @JohnCFierce

@DamianFierce: $BIIB investigator declined to color in 54-week 6mg data with my pen but agreed there should be a lottery. Image | Follow @DamianFierce

> Not everyone in biotechnology is finding fame and fortune on Wall Street. Gene therapy player BioCardia failed to float its IPO, deciding to postpone the offering to a later date. Story

> San Diego-based Dauntless Pharmaceuticals has launched with a $12 million round backed by CEO Joel Martin and Sofinnova. The money will be used to advance DP1038, a preclinical-stage drug for endocrine cancers. Release

> The UK's Oxford Nanopore Technologies raised $109 million. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Implanting a titanium tube inside damaged bones improves procedure to ward off amputations. Story | Follow @FierceMedDev

@EmilyWFierce: A U.K. research firm is developing tech to make diagnostic tests with an inkjet printer. More from the BBJ | Follow @EmilyWFierce

> iHealth expands its retail, connected medical device empire and looks to move into corporations, hospitals. Article

> Propeller Health receives FDA clearance to sell its app and sensor to patients using Glaxo's inhalers. More

> Bloomberg: St. Jude Medical discussing takeover of Thoratec. Report

Pharma News

@FiercePharma: Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar. FiercePharmaMarketing report | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Horizon hikes Depomed offer to $2B in bid for 'friendly' deal talks. Report | Follow @CarlyHFierce

> Drugmakers like Gilead, Mylan and Novo, not Big Pharma, are job creators. More

> Should J&J break up? Get ready for a new round of debate. Story

Biotech Research News

> Meta-analysis: Avandia's impact on Parkinson's should spur new research. Report

> Animal study highlights role of mast cells in chronic eye diseases. More

> Specialized cells in Alzheimer's could be used for diagnosis, drugs. Report

> Yale scientists highlight a promising eczema study for Pfizer's Xeljanz. Story

> NYU Langone team spotlights new antibodies for Alzheimer's, Parkinson's. Article

Diagnostics News

> Illumina launches new lab service for HiSeq X sequencing systems. More

> Alere revs up engine with new deals and win for quick strep test. Story

> Exact Sciences reveals $179M public offering amid slumping Q2 sales. News

> Oxford Nanopore reels in $109M to ramp up R&D. Item

> Theranos inks Medicaid deal and snags CLIA waiver to expand Dx reach. Article

Pharma Marketing News

> Will Genzyme's Fabry pill only steal sales from Fabrazyme? Not if it acts like Cerdelga. More

> Abbott boosts generic drug sales by 31% in strong Q2 showing. Item

> Sanofi Pasteur drafts Bollywood star to talk up flu shots in India. Report

> What's in a pill color? Consumers see messages in red, blue, green and white. Story

> The PCSK9 countdown: Amgen's Repatha wins EU race, with Sanofi's Praluent up Friday at FDA. Article

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.